Potent inducer of anemia

Natural inhibitor of microRNA-21, reducing growth of cancer cells

Novel 11β-HSD1 inhibitor

Selective 11beta-hydroxysteroid dehydrogenase type 1 (11betaHSD1) inhibitor

Novel BB2 receptor antagonist. attenuating the feeding responses evoked by exogenous gastrin releasing peptide-29

Highly selective inhibitor of AChE

Novel Gemini vitamin D analog, targeting CD44-STAT3 signaling and inhibiting breast cancer invasion

Novel promising spectroscopic probe for inositol 5-phosphatase(s)

Novel potent and selective PTP-1B inhibitor

β-Hairpin Octapeptide, acting as a potent mouse melanocortin-4 receptor (mMC4R) antagonist

Natural inhibitor of BACE1

Novel sensitizer of BRAF wild-type melanoma cells to vemurafenib, significantly reducing melanoma cell viability, with limited toxicity for normal human fibroblasts

Novel broad-spectrum intracellular targeting antibacterial agent, interacting with the 70S ribosome of E. coli and inhibiting its protein synthesis, demonstrating superior clearance of bacteria from the spleen, liver, and kidneys of mice, infected with S.

Novel broad-spectrum intracellular targeting antibacterial agent, interacting with the 70S ribosome of E. coli and inhibiting its protein synthesis, demonstrating superior clearance of bacteria from the spleen, liver, and kidneys of mice, infected with S.

FPP analogue, bearing an alkyne group to allow for post-prenylation protein labeling

Novel multi-functional resveratrol derivative for the treatment of atrial fibrillation

Novel selective activator for TREK, against other two-pore domain K (K2P) channels

First-In-Class Inhibitor of the Interaction between Bacterial RNA Polymerase and Sigma Initiation Factor, Affecting the Viability and Toxin Release of Streptococcus pneumoniae

The first C3b-binding complement inhibitor, inhibiting the formation of the membrane attack complex (MAC) by preventing cleavage of C5

Inducer of mast cell degranulation

Novel potent inhibitor of botulinum neurotoxin serotype E (BoNT/E)

Novel covalent cross-linker to the SARS-CoV-2 frameshifting element (FSE), directly targeting engagement of the SARS-CoV-2 FSE in cells, dose dependently reducing frameshifting in cells expressing the SARS-CoV-2 FSE, with no significant effect on frameshi